PBPIA
KRTX

Pivotal bioVenture Partners Investment Advisor’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-797,008
Closed -$252M – 12
2023
Q4 		$252M Hold
797,008
– – 63.99% 1
2023
Q3 		$135M Buy
797,008
+15,000
+2% +$2.82M 53.75% 1
2023
Q2 		$170M Hold
782,008
– – 55.9% 1
2023
Q1 		$142M Buy
782,008
+16,113
+2% +$3.08M 58.49% 1
2022
Q4 		$150M Hold
765,895
– – 65.45% 1
2022
Q3 		$172M Sell
765,895
-115,563
-13% -$23.4M 62.95% 1
2022
Q2 		$112M Buy
881,458
+28,750
+3% +$3.3M 56.18% 1
2022
Q1 		$108M Hold
852,708
– – 51.15% 1
2021
Q4 		$112M Hold
852,708
– – 46.71% 1
2021
Q3 		$104M Hold
852,708
– – 36.87% 1
2021
Q2 		$97.2M Sell
852,708
-56,000
-6% -$6.55M 38.31% 1
2021
Q1 		$109M Sell
908,708
-174,636
-16% -$19.8M 35.05% 1
2020
Q4 		$110M Buy
+1,083,344
New +$100M 36.29% 1

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's KRTX Position: Q1 2024 in Review

Pivotal bioVenture Partners Investment Advisor sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 797,008 shares — an estimated $252M sold.

Pivotal bioVenture Partners Investment Advisor first reported a position in KRTX in Q4 2020 and held it in 13 quarters. The position peaked at $252M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Pivotal bioVenture Partners Investment Advisor reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Pivotal bioVenture Partners Investment Advisor sold 797,008 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $252M.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2020 and held it in 13 quarters.
  • Pivotal bioVenture Partners Investment Advisor's Karuna Therapeutics, Inc. Common Stock position peaked at $252M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2024, filed 14 May 2024.